Articles By Estel Grace Masangkay

  1. Novartis Returns HCV Drug Rights, Ends Agreement With Enanta 10/6/2014

    R&D biotech firm Enanta Pharmaceuticals announced that it will be regaining full rights of investigational hepatitis C treatment EDP-239 from its ex-partner Novartis.

  2. Novartis' Zykadia Extended PFS In ALK+ NSCLC 10/3/2014

    Novartis reported positive new data from its pivotal study showing that Zykadia (ceritinib) extended progression-free survival (PFS) for an average of over 18 months in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who took the drug as their first ALK inhibitor.

  3. Janssen's Rezolsta For HIV Backed By CHMP 10/3/2014

    Janssen-Cilag International announced that it has received the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for Rezolsta (darunavir/cobicistat) for use with other antiretroviral therapies against human immunodeficiency virus-1 (HIV-1) infection in adult patients.

  4. FDA Grants Triple Orphan Designations To CytRx Lead Drug 10/3/2014

    Biopharmaceutical R&D firm CytRx announced that its lead drug candidate aldoxorubicin has been awarded multiple Orphan Drug Designations by the U.S. Food and Drug Administration (FDA) in three indications. These indications include glioblastoma multiforme (GBM), small cell lung cancer, and ovarian cancer.

  5. Bayer Completes Purchase Of Merck's OTC Business For $14.2B 10/3/2014

    Bayer announced that it has completed its acquisition of fellow pharma giant Merck’s consumer care business after receiving the necessary antitrust approvals.

  6. Janssen-Cilag Posts Phase 3 Data For Zytiga In Prostate Cancer 10/2/2014

    Janssen-Cilag International reported positive data from the final analysis of its Phase 3 trial investigating Zytiga in male patients with metastatic castration-resistant prostate cancer (mCPRPC) who have not yet undergone chemotherapy.

  7. AstraZeneca Posts Early Data For Anti-Cancer Combo At ESMO 10/2/2014

    AstraZeneca and its global biologics R&D arm MedImmune reported promising early results from the ongoing Phase 1 study of MEDI4736 (PD-L1) and tremelimumab (CTLA-4) combination in patients with non-small cell lung cancer (NSCLC) who have already undergone prior treatment.

  8. CHMP Recommends Novartis' Signifor For Acromegaly 10/1/2014

    Novartis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for the company’s Signifor (pasireotide) long-acting release (LAR) formulation as treatment for certain adult patients with acromegaly.

  9. Novartis Posts Positive Phase 3 Data For Afinitor In pNET 9/30/2014

    Novartis reported positive final results from a Phase 3 trial investigating Afinitor (everolimus) tablets versus placebo in patients with pancreatic neuroendocrine tumors (pNET).

  10. Merck Posts Early Data For Keytruda In Gastric And Bladder Cancer 9/30/2014

    Merck reported positive early trial results for its anti-PD-1 therapy pembrolizumab in both advanced gastric cancer and advanced urothelial cancer or bladder cancer.